Lixte Biotechnology Holdings, Inc.
LIXT
$5.16
$0.122.38%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.85M | 3.66M | 2.53M | 2.61M | 2.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.11M | 3.90M | 3.08M | 3.31M | 3.57M |
| Operating Income | -5.11M | -3.90M | -3.08M | -3.31M | -3.57M |
| Income Before Tax | -6.01M | -4.08M | -3.09M | -3.32M | -3.59M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.01 | -4.08 | -3.09 | -3.32 | -3.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.01M | -4.08M | -3.09M | -3.32M | -3.59M |
| EBIT | -5.11M | -3.90M | -3.08M | -3.31M | -3.57M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.22 | -1.18 | -1.29 | -1.45 | -1.59 |
| Normalized Basic EPS | -0.76 | -0.73 | -0.80 | -0.91 | -1.00 |
| EPS Diluted | -1.22 | -1.18 | -1.29 | -1.45 | -1.59 |
| Normalized Diluted EPS | -0.76 | -0.73 | -0.80 | -0.91 | -1.00 |
| Average Basic Shares Outstanding | 19.32M | 13.61M | 9.69M | 9.22M | 9.00M |
| Average Diluted Shares Outstanding | 19.32M | 13.61M | 9.69M | 9.22M | 9.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |